Description
Retatrutide (LY3437943) is an investigational peptide being studied for its activity at three metabolic hormone receptors: GIP, GLP-1, and glucagon. Because it acts on all three pathways, it is commonly described as a GIP/GLP-1/glucagon triple agonist.
Research has evaluated retatrutide in areas including body-weight reduction, glucose regulation, and metabolic health. In clinical trials, investigators have observed substantial reductions in body weight, along with improvements in several metabolic measures.
Five potential advantages being investigated are:
Significant weight loss — Clinical trials have shown substantial reductions in body weight.
Reduced appetite — It acts on multiple hormone receptors involved in appetite and energy balance.
Improved blood sugar control — Studies have reported reductions in blood glucose and HbA1c.
Potential cardiovascular/metabolic benefits — Research has found improvements in measures such as blood pressure and blood lipids.
Multiple mechanisms of action — Retatrutide activates GIP, GLP-1, and glucagon receptors, which may produce broader metabolic effects than drugs acting on only one or two of these pathways.
Reviews
There are no reviews yet.